Recursion (RXRX) insider sales include 100,000-share Form 144 notice
Rhea-AI Filing Summary
Recursion Pharmaceuticals, Inc. (RXRX) filed a Form 144 notice reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage, with an aggregate market value of
The filing also discloses multiple recent sales by related parties during the past three months: combined transactions on
Positive
- Proper Rule 144 disclosure filed showing broker, amount, and planned sale date
- Shares originated as founders' compensation on
09/01/2016 , documenting acquisition history
Negative
- Large recent insider sales reported in the past three months (e.g., 500,000 shares sold on
08/11/2025 for$2,640,000 ) which may increase share supply - Additional planned sale of 100,000 shares on
10/10/2025 could further reduce insider ownership near-term
Insights
TL;DR: A founder-originated block of 100,000 shares is slated for sale, amid multiple large insider sales this quarter.
The filing identifies 100,000 Class A shares acquired as founders' shares on
Recent reported sales by related parties show substantial insider liquidity: for example, 500,000 shares sold on
TL;DR: The transaction is routine Rule 144 disclosure but signals near-term insider exits that investors may note.
The notice confirms the securities were issued as compensation and were acquired in
Material items to watch over the next month include whether the
FAQ
What does the RXRX Form 144 disclose?
Who originally acquired the shares being sold in the RXRX filing?
Have insiders sold RXRX shares recently?
On which exchange will the shares be sold?
Does the filing state any undisclosed material information?